Targeting SOST using a small-molecule compound retards breast cancer bone metastasis
Abstract Background Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone formation, and an attractive target for treatment of osteoporosis. Howeve...
Saved in:
| Main Authors: | Lisha Sun, Yixiao Zhang, Guanglei Chen, Yaoting Ji, Qingtian Ma, Xinbo Qiao, Sijin Wu, Lin Zhou, Jiawen Bu, Xudong Zhu, Xiaoying Zhang, Xiaofan Jiang, Chao Liu, Xinnan Li, Yang Liu, Yongliang Yang, Caigang Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-022-01697-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of SOST in Response to Mechanical Stimulation in Bone and Extraosseous Organs
by: Minyou Chen, et al.
Published: (2025-06-01) -
Novel Loss of Function Variant in SOST From Chinese Family Results in Sclerosteosis 1
by: Yufan Guo, et al.
Published: (2025-07-01) -
Activation of sclerostin inhibits Isg20-Mediated aerobic glycolysis ameliorating renal Fibrosis: the renoprotective mechanism of hederagenin in CKD
by: Rang-yue Han, et al.
Published: (2025-09-01) -
Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer
by: Yixiao Zhang, et al.
Published: (2022-03-01) -
Small molecule inhibitors targeting the cancers
by: Gui‐Hong Liu, et al.
Published: (2022-12-01)